ALKERMES | ALKS - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
AbbVie USD 3.58B 316M 2026-03
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
ALKERMES USD 264.59M 77.4M 2026-03
Amgen USD 1.58B 354M 2026-03
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 151M 21M 2026-03
J&J USD 6.42B 381M 2026-06
Malin Corporation EUR 1.1M 400K 2024-12
Merck USD 2.67B 180M 2026-03
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Otsuka Holdings JPY 259.49B 18.81B 2026-03
Ovoca Bio EUR 632K 2.33M 2025-06
Pfizer USD 2.92B 1.16B 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03